Sleep apnoea and its consequences: from animal models to precision medicine
Abstract
A European Respiratory Society research seminar entitled "Sleep Apnoea and Its Consequences: From Animal Models to Precision Medicine" was held in January 2024 in Lisbon, Portugal. It provided an in-depth analysis of the current landscape and future directions in OSA research, integrating recent findings from metabolomics, animal models, clinical predictors of cardiometabolic consequences of OSA, artificial intelligence (AI), and advances in diagnostic algorithms. This article presents a narrative review of the seminar's key discussions and conclusions. The limitations of current randomized controlled trials (RCTs) in assessing OSA treatment, such as low adherence and patient selection bias (e.g., absence of sleepiness or severe hypoxemia), were critically discussed. The expert panel recommended the use of real-world data, including patients commonly seen in clinical practice, and the use of digital tools for real-time monitoring of adherence and side effects. The concept of platform "disease-focused" trials was discussed as a more efficient and adaptable research design that could allow clinical trials to be more representative of the general OSA population and to compare CPAP with emerging treatments such as new drugs, devices and lifestyle interventions to gain a broader understanding of effective management strategies. The seminar concluded that a multifaceted approach to OSA research that leverages the strengths of animal models, advanced AI, metabolomics, and improved diagnostic algorithms is needed to gain deeper insights into the mechanisms of OSA and its treatment response. This new approach, coupled with new "platform" clinical trial designs, could contribute to improved outcomes in patients with OSA.
Related
- De-escalating Therapy in Obstructive Sleep Apnoea After Glucagon-Like Peptide-1 Receptor Agonist-Induced Weight Loss: A Narrative Review
- Accelerometer-derived 24-hour behavior composition and incident clinically diagnosed sleep apnoea: a prospective cohort study
- Association between the triglyceride-glucose-waist circumference index and obstructive sleep apnoea: a hospital-based case-control study in China and the development of machine learning models.
- Beyond the Apnoea–Hypopnoea Index: Towards Personalised Care of Patients with Suspected Obstructive Sleep Apnoea Through Clinical Phenotyping and Physiological Stratification
- Orofacial Myofunctional Therapy to Treat Residual Obstructive Sleep Apnoea in Children Treated with Adenotonsillectomy and Maxillary Expansion: An Interventional Study
BibTeX
@article{heinzer2026sleep,
title = {{Sleep apnoea and its consequences: from animal models to precision medicine}},
author = {Raphael Heinzer and Jean-Louis Pepin and Silke Ryan and Claire Arnaud and Margaux Blanchard and Rene Cortese and Carolina Lombardi and Oren Cohen and Adrien Waeber and Martino Pengo and Yuksel Peker and Jordi de Batlle and Walter Mcnicholas and Winfried Randerath and Frederic Gagnadoux and Ali Azarbarzin and Manuel Sanchez-De-La-Torre},
journal = {Sleep Medicine},
year = {2026},
month = aug,
doi = {10.1016/j.sleep.2026.108777},
url = {https://hal.science/hal-05732532v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Sleep apnoea and its consequences: from animal models to precision medicine
AU - Raphael Heinzer
AU - Jean-Louis Pepin
AU - Silke Ryan
AU - Claire Arnaud
AU - Margaux Blanchard
AU - Rene Cortese
AU - Carolina Lombardi
AU - Oren Cohen
AU - Adrien Waeber
AU - Martino Pengo
AU - Yuksel Peker
AU - Jordi de Batlle
AU - Walter Mcnicholas
AU - Winfried Randerath
AU - Frederic Gagnadoux
AU - Ali Azarbarzin
AU - Manuel Sanchez-De-La-Torre
PY - 2026
DA - 2026/08/31
JO - Sleep Medicine
DO - 10.1016/j.sleep.2026.108777
UR - https://hal.science/hal-05732532v1
AB - A European Respiratory Society research seminar entitled "Sleep Apnoea and Its Consequences: From Animal Models to Precision Medicine" was held in January 2024 in Lisbon, Portugal. It provided an in-depth analysis of the current landscape and future directions in OSA research, integrating recent findings from metabolomics, animal models, clinical predictors of cardiometabolic consequences of OSA, artificial intelligence (AI), and advances in diagnostic algorithms. This article presents a narrative review of the seminar's key discussions and conclusions. The limitations of current randomized controlled trials (RCTs) in assessing OSA treatment, such as low adherence and patient selection bias (e.g., absence of sleepiness or severe hypoxemia), were critically discussed. The expert panel recommended the use of real-world data, including patients commonly seen in clinical practice, and the use of digital tools for real-time monitoring of adherence and side effects. The concept of platform "disease-focused" trials was discussed as a more efficient and adaptable research design that could allow clinical trials to be more representative of the general OSA population and to compare CPAP with emerging treatments such as new drugs, devices and lifestyle interventions to gain a broader understanding of effective management strategies. The seminar concluded that a multifaceted approach to OSA research that leverages the strengths of animal models, advanced AI, metabolomics, and improved diagnostic algorithms is needed to gain deeper insights into the mechanisms of OSA and its treatment response. This new approach, coupled with new "platform" clinical trial designs, could contribute to improved outcomes in patients with OSA.
SN - 1389-9457
SN - 1878-5506
ER -